However, to the best of our knowledge, no head-to-head meta-analyses have evaluated GV, including net changes in MAGE, MBG levels, and percentage of time maintaining euglycemia, during diabetes treatment with SGLT-2 inhibitors or GLP-1 agonists. This evidence concerns the gene SLC5A2 and diabetes mellitus.